Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: A systematic review of studies on morbidity

Clinical Endocrinology

Volumn 81, Issue 1, 2014, Pages 1-14

  Van Bunderen, Christa C ^a   Van Varsseveld, Nadège C ^a   Erfurth, Eva Marie ^b   Ket, Johannes C F ^c   Drent, Madeleine L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HYDROCORTISONE; HYPOPHYSIS HORMONE; HUMAN GROWTH HORMONE;

ACROMEGALY; ADULT DISEASE; ARTERIAL WALL THICKNESS; BODY COMPOSITION; BONE METABOLISM; BONE MINERAL; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER SURVIVOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHILDHOOD CANCER; CLINICAL PRACTICE; CRANIOPHARYNGIOMA; CUSHING DISEASE; DIABETES MELLITUS; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HEALTH CARE COST; HEART INFARCTION; HEART LEFT VENTRICLE MASS; HEART STROKE VOLUME; HIGH RISK PATIENT; HUMAN; HYDROCORTISONE URINE LEVEL; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; HYPOPITUITARISM; INSULIN SENSITIVITY; MORBIDITY; MUSCLE STRENGTH; NONFUNCTIONING PITUITARY ADENOMA; OSTEOLYSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROCAM SCORE; PROGRESSION FREE SURVIVAL; PROLACTINOMA; RECURRENT DISEASE; REVIEW; SPINE FRACTURE; SPINE MALFORMATION; SYSTEMATIC REVIEW; ADULT; CARDIOVASCULAR DISEASES; DEFICIENCY; FRACTURES, BONE; HORMONE SUBSTITUTION; NEOPLASMS; STROKE;

ADULT; CARDIOVASCULAR DISEASES; FRACTURES, BONE; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; NEOPLASMS; STROKE;

EID: 84902493825     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12477     Document Type: Review

References (75)

1. Buchanan, C.R., Preece, M.A., &, Milner, R.D., (1991) Mortality, neoplasia, and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom. BMJ, 302, 824-828.
2. de Boer, H., Blok, G.J., &, Van der Veen, E.A., (1995) Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews, 16, 63-86.
3. Rosèn, T., &, Bengtsson, B.A., (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet, 336, 285-288.
4. Ahmad, A.M., Hopkins, M.T., Thomas, J., et al,. (2001) Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement. Clinical Endocrinology (Oxford), 54, 709-717.
5. Maison, P., Griffin, S., Nicoue-Beglah, M., et al,. (2004) Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 89, 2192-2199.
6. de Boer, H., Blok, G.J., Voerman, B., et al,. (1995) The optimal growth hormone replacement dose in adults, derived from bioimpedance analysis. Journal of Clinical Endocrinology and Metabolism, 80, 2069-2076.
7. Jorgensen, J.O., Pedersen, S.A., Thuesen, L., et al,. (1989) Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet, 1, 1221-1225.
8. Salomon, F., Cuneo, R.C., Hesp, R., et al,. (1989) The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. New England Journal of Medicine, 321, 1797-1803.
9. Weaver, J.U., Monson, J.P., Noonan, K., et al,. (1995) The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. Journal of Clinical Endocrinology and Metabolism, 80, 153-159.
10. Ehrnborg, C., Hakkaart-Van Roijen, L., Jonsson, B., et al,. (2000) Cost of illness in adult patients with hypopituitarism. Pharmacoeconomics, 17, 621-628.
11. Hakkaart-Van Roijen, L., Beckers, A., Stevenaert, A., et al,. (1998) The burden of illness of hypopituitary adults with growth hormone deficiency. Pharmacoeconomics, 14, 395-403.
12. Appelman-Dijkstra, N.M., Claessen, K.M.J.A., Roelfsema, F., et al,. (2013) Therapy of Endocrine disease: long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. European Journal of Endocrinology, 169, R1-R14.
13. Erfurth, E.M., (2013) Update in mortality in GH-treated patients. Journal of Clinical Endocrinology and Metabolism, 98, 4219-4226.
14. Schneider, H.J., Klotsche, J., Saller, B., et al,. (2008) Associations of age-dependent IGF-I SDS with cardiovascular diseases and risk conditions: cross-sectional study in 6773 primary care patients. European Journal of Endocrinology, 158, 153-161.
15. Renehan, A.G., Zwahlen, M., Minder, C., et al,. (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet, 363, 1346-1353.
16. van Bunderen, C.C., van Nieuwpoort, I.C., van Schoor, N.M., et al,. (2010) The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study. Journal of Clinical Endocrinology and Metabolism, 95, 4616-4624.
17. Hew, F.L., Koschmann, M., Christopher, M., et al,. (1996) Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. Journal of Clinical Endocrinology and Metabolism, 81, 555-564.
18. O'Neal, D.N., Kalfas, A., Dunning, P.L., et al,. (1994) The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis. Journal of Clinical Endocrinology and Metabolism, 79, 975-983.
19. Liberati, A., Altman, D.G., Tetzlaff, J., et al,. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine, 6, e1000100.
20. von Elm, E., Altman, D.G., Egger, M., et al,. (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet, 370, 1453-1457.
21. Schneider, H.J., Klotsche, J., Wittchen, H.U., et al,. (2011) Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. Clinical Endocrinology (Oxford), 75, 825-830.
22. Bulow, B., Hagmar, L., Eskilsson, J., et al,. (2000) Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. Journal of Clinical Endocrinology and Metabolism, 85, 574-584.
23. Svensson, J., Bengtsson, B.A., Rosen, T., et al,. (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism, 89, 3306-3312.
24. Stochholm, K., Laursen, T., Green, A., et al,. (2008) Morbidity and GH deficiency: a nationwide study. European Journal of Endocrinology, 158, 447-457.
25. Erfurth, E.M., Siesjo, P., &, Bjork-Eriksson, T., (2013) Pituitary disease mortality: is it fiction? Pituitary, 16, 402-412.
26. Colao, A., Di Somma, C., Cuocolo, A., et al,. (2005) Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a two-year open, prospective study in young adult men and women with severe GH deficiency. Journal of Clinical Endocrinology and Metabolism, 90, 5146-5155.
27. Colao, A., Di Somma, C., Spiezia, S., et al,. (2008) Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism, 93, 3416-3424.
28. Burman, P., Mattsson, A.F., Johannsson, G., et al,. (2013) Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. Journal of Clinical Endocrinology and Metabolism, 98, 1466-1475.
29. Hartman, M.L., Xu, R., Crowe, B.J., et al,. (2013) Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. Journal of Clinical Endocrinology and Metabolism, 98, 980-988.
30. Gaillard, R.C., Mattsson, A.F., Akerblad, A.C., et al,. (2012) Overall and cause-specific mortality in GH-deficient adults on GH replacement. European Journal of Endocrinology, 166, 1069-1077.
31. van Bunderen, C.C., van Nieuwpoort, I.C., Arwert, L.I., et al,. (2011) Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. Journal of Clinical Endocrinology and Metabolism, 96, 3151-3159.
32. Holmer, H., Svensson, J., Rylander, L., et al,. (2007) Nonfatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on hormone replacement including growth hormone. Journal of Clinical Endocrinology and Metabolism, 92, 3560-3567.
33. Abs, R., Bengtsson, B.A., Hernberg-Stahl, E., et al,. (1999) GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clinical Endocrinology (Oxford), 50, 703-713.
34. Koranyi, J., Svensson, J., Gotherstrom, G., et al,. (2001) Baseline characteristics and the effects of five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: a comparative, prospective study. Journal of Clinical Endocrinology and Metabolism, 86, 4693-4699.
35. Rosen, T., Wilhelmsen, L., Landin-Wilhelmsen, K., et al,. (1997) Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. European Journal of Endocrinology, 137, 240-245.
36. Wuster, C., Abs, R., Bengtsson, B.A., et al,. (2001) The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. Journal of Bone and Mineral Research, 16, 398-405.
37. Abs, R., Mattsson, A.F., Bengtsson, B.A., et al,. (2005) Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database. Growth Hormone and IGF Research, 15, 349-359.
38. Tritos, N.A., &, Biller, B.M.K., (2009) Growth hormone and bone. Current opinion in Endocrinology, Diabetes, and Obesity, 16, 415-422.
39. Gotherstrom, G., Svensson, J., Koranyi, J., et al,. (2001) A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. Journal of Clinical Endocrinology and Metabolism, 86, 4657-4665.
40. Johansson, A.G., Engstrom, B.E., Ljunghall, S., et al,. (1999) Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. Journal of Clinical Endocrinology and Metabolism, 84, 2002-2007.
41. Elbornsson, M., Gotherstrom, G., Bosaeus, I., et al,. (2012) Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. European Journal of Endocrinology, 166, 787-795.
42. Holmer, H., Svensson, J., Rylander, L., et al,. (2007) Fracture incidence in GH-deficient patients on complete hormone replacement including GH. Journal of Bone and Mineral Research, 22, 1842-1850.
43. Mazziotti, G., Porcelli, T., Bianchi, A., et al,. (2010) Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. European Journal of Endocrinology, 163, 15-20.
44. Mazziotti, G., Bianchi, A., Bonadonna, S., et al,. (2006) Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. Journal of Bone and Mineral Research, 21, 520-528.
45. Bates, A.S., Van't Hoff, W., Jones, P.J., et al,. (1996) The effect of hypopituitarism on life expectancy. Journal of Clinical Endocrinology and Metabolism, 81, 1169-1172.
46. Rosen, T., Eden, S., Larson, G., et al,. (1993) Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinologica, 129, 195-200.
47. Nilsson, B., Gustavasson-Kadaka, E., Bengtsson, B.A., et al,. (2000) Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. Journal of Clinical Endocrinology and Metabolism, 85, 1420-1425.
48. Bulow, B., Hagmar, L., Mikoczy, Z., et al,. (1997) Increased cerebrovascular mortality in patients with hypopituitarism. Clinical Endocrinology (Oxford), 46, 75-81.
49. Tomlinson, J.W., Holden, N., Hills, R.K., et al,. (2001) Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet, 357, 425-431.
50. Popovic, V., Damjanovic, S., Micic, D., et al,. (1998) Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group. Clinical Endocrinology (Oxford), 49, 441-445.
51. Erfurth, E.M., Bulow, B., Mikoczy, Z., et al,. (2001) Incidence of a second tumor in hypopituitary patients operated for pituitary tumors. Journal of Clinical Endocrinology and Metabolism, 86, 659-662.
52. Erfurth, E.M., Bulow, B., Mikoczy, Z., et al,. (2001) Is there an increase in second brain tumours after surgery and irradiation for a pituitary tumour? Clinical Endocrinology (Oxford), 55, 613-616.
53. Sattler, M.G.A., van Beek, A.P., Wolffenbuttel, B.H.R., et al,. (2012) The incidence of second tumours and mortality in pituitary adenoma patients treated with postoperative radiotherapy versus surgery alone. Radiotherapy and Oncology, 104, 125-130.
54. Popovic, V., Mattsson, A.F., Gaillard, R.C., et al,. (2010) Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). Journal of Clinical Endocrinology and Metabolism, 95, 4449-4454.
55. Bell, J., Parker, K.L., Swinford, R.D., et al,. (2010) Long-term safety of recombinant human growth hormone in children. Journal of Clinical Endocrinology and Metabolism, 95, 167-177.
56. Swerdlow, A.J., Higgins, C.D., Adlard, P., et al,. (2002) Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet, 360, 273-277.
57. Ergun-Longmire, B., Mertens, A.C., Mitby, P., et al,. (2006) Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. Journal of Clinical Endocrinology and Metabolism, 91, 3494-3498.
58. Woodmansee, W.W., Zimmermann, A.G., Child, C.J., et al,. (2013) Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS. European Journal of Endocrinology, 168, 565-573.
59. Wilton, P., Mattsson, A.F., &, Darendeliler, F., (2010) Growth hormone treatment in children is not associated with an increase in the incidence of cancer: experience from KIGS (Pfizer International Growth Database). Journal of Pediatrics, 157, 265-270.
60. Carel, J.C., Ecosse, E., Landier, F., et al,. (2012) Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. Journal of Clinical Endocrinology and Metabolism, 97, 416-425.
61. Savendahl, L., Maes, M., Albertsson-Wikland, K., et al,. (2012) Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. Journal of Clinical Endocrinology and Metabolism, 97, E213-E217.
62. Mo, D., Hardin, D., Erfurth, E., et al,. (2013) Adult mortality or morbidity is not increased in childhood-onset growth hormone deficient patients who received pediatric GH treatment: an analysis of the Hypopituitary Control and Complications Study (HypoCCS). Pituitary [Epub ahead of print] DOI 10.1007/s11102-013-0529-6.
63. Stochholm, K., Juul, S., Christiansen, J.S., et al,. (2012) Mortality and socioeconomic status in adults with childhood onset GH deficiency (GHD) is highly dependent on the primary cause of GHD. European Journal of Endocrinology, 167, 663-670.
64. Olsson, D.S., Buchfelder, M., Wiendieck, K., et al,. (2012) Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up. European Journal of Endocrinology, 166, 1061-1068.
65. Mackenzie, S., Craven, T., Gattamaneni, H.R., et al,. (2011) Long-term safety of growth hormone replacement after CNS irradiation. Journal of Clinical Endocrinology and Metabolism, 96, 2756-2761.
66. Arnold, J.R., Arnold, D.F., Marland, A., et al,. (2009) GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clinical Endocrinology (Oxford), 70, 435-438.
67. Olsson, D.S., Buchfelder, M., Schlaffer, S., et al,. (2009) Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy. European Journal of Endocrinology, 161, 663-669.
68. Buchfelder, M., Kann, P.H., Wuster, C., et al,. (2007) Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study. European Journal of Endocrinology, 157, 149-156.
69. Karavitaki, N., Warner, J.T., Marland, A., et al,. (2006) GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clinical Endocrinology (Oxford), 64, 556-560.
70. Hatrick, A.G., Boghalo, P., Bingham, J.B., et al,. (2002) Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? European Journal of Endocrinology, 146, 807-811.
71. Child, C.J., Zimmermann, A.G., Woodmansee, W.W., et al,. (2011) Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study. European Journal of Endocrinology, 165, 217-223.
72. Abs, R., Mattsson, A.F., Thunander, M., et al,. (2013) Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. European Journal of Endocrinology, 168, 297-305.
73. Attanasio, A.F., Jung, H., Mo, D., et al,. (2011) Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. Journal of Clinical Endocrinology and Metabolism, 96, 2255-2261.
74. Cutfield, W.S., Wilton, P., Bennmarker, H., et al,. (2000) Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet, 355, 610-613.
75. Luger, A., Mattsson, A.F., Koltowska-Haggstrom, M., et al,. (2012) Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: a long-term observational study. Diabetes Care, 35, 57-62.